Digestive System Adenocarcinoma — Trials

Digestive System Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,373
Recruiting: 799
Ph III recruiting: 82
Growth YoY: +14.4%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (618)

clinicaltrialsPublishedShowing 101–136 of 136 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06958484	Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence	not yet recruiting	Phase 2	60	The Affiliated Hospital of Xuzhou Medical UniversityOTHER	0	May 6, 2025	clinicaltrials
NCT06942767	Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	not yet recruiting	Phase 2	100	Qilu Pharmaceutical Co., Ltd.